Medscape |
EMA OKs Nucala for Severe Refractory Eosinophilic Asthma
Medscape The European Medicines Agency (EMA) has approved mepolizumab (Nucala, GlaxoSmithKline) as an add-on treatment for severe refractory eosinophilic asthma in adults in the 31 European countries covered by the EMA, according to a company statement. GSK gets European marketing rights for Nucala to treat asthma EU OK for GSK's novel asthma biologic Nucala Now Available for Severe Asthma |
View full post on asthma – Google News